. . . . . . . "[Patients with untreated HER2-negative MBC were randomized (1:1) to receive 28-day cycles of paclitaxel 90�mg/m(2) IV (days 1, 8, and 15) and bevacizumab 10�mg/kg IV (days 1, 15) with either everolimus 10�mg (Arm 1) or placebo (Arm 2) daily.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:17:47+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .